Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
https://doi.org/10.22416/1382-4376-2021-31-6-7-15
Abstract
Aim. A general review of treatment approaches to ulcerative colitis (UC) and the importance of oral 5-aminosalicylic acid (5-ASA) for its routine outpatient management.
Key points. The choice of drug therapy for UC remission induction and maintenance is linked to the intestinal lesion extent and disease attack severity. The 5-ASA therapy remains the mainstay UC treatment in routine outpatient practice, with prescription rate of 80–90%. Oral 5-ASA drugs are often used in monotherapy or when oral and rectal 5-ASAs are recommended in combination. As a sustained-release medication, the MMX mesalazine multi-matrix delivery system provides for higher active substance dosages along entire colonic mucosa, including its distal portions. A higher active substance dosage per tablet reduces the number of intakes and ensures a better patient adherence, both in terms of daily and long-term therapy.
Conclusion. The 5-ASA drugs are most commonly prescribed in outpatient practice. Sustained-release 5-ASAs provide for a more effective active ingredient distribution at higher dosages along colonic mucosa.
About the Authors
Yu. P. Uspenskiy
Saint-Petersburg State Pediatric Medical University;
Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
Yury P. Uspenskiy — Dr. Sci. (Med.), Prof., Head of the Chair of Intermediate Therapy named after Prof. V.A. Waldman, 194100, St. Petersburg, Litovskaya str., 2;
Prof., Chair of Internal Medicine, Faculty of Dentistry, 197022, St. Petersburg, Lva Tolstogo str., 6/8
S. V. Ivanov
Pavlov First SaintPetersburg State Medical University;
Saint-Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Sergei V. Ivanov — Cand. Sci. (Med.), Assoc. Prof., Chair of Internal Medicine, Faculty of Dentistry, 197022, St. Petersburg, Lva Tolstogo str., 6/8;
Assoc. Prof., Chair of Intermediate Therapy named after Prof. V.A. Waldman, 194100, St. Petersburg, Litovskaya str., 2
Yu. A. Fominykh
Saint Petersburg State Pediatric Medical University;
Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
Yulia A. Fominykh — Dr. Sci. (Med.), Prof., Chair of Intermediate Therapy named after Prof. V.A. Waldman, 194100, St. Petersburg, Litovskaya str., 2;
Assoc. Prof., Chair of Internal Medicine, Faculty of Dentistry, 197022, St. Petersburg, Lva Tolstogo str., 6/8
References
1. Ivashkin V.T., Shelygin Yu.A., Abdulganieva D.I., Abdulkhakov R.A., Alekseyeva O.P., Achkasov S.I., et al. Recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of adult patients with ulcerative colitis. Rus J Gastroenterol Hepatol Coloproctol. 2015;1:48–65 (In Russ.).
2. Ivashkin V.T., Shelygin Yu.A., Belousova E.A., Abdulganieva D.I., Alekseyeva O.P., Achkasov S.I., et al. Draft clinical guidelines for the diagnosis and treatment of ulcerative colitis. Coloproctology. 2019;18(4):7–36 (In Russ.).
3. Knyazev O.V. Shkurko T.V., Fadeeva N.A., Bakulin I.G., Bordin D.S. Epidemiology of chronic inflammatory bowel diseases. Yesterday, today, tomorrow. Experimental and Clinical Gastroenterology. 2017;139(3):4–12 (in Russ.).
4. Harbord M., Eliakim R., Bettenworth D., Karmiris K., Katsanos K., Kopylov U., et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(7):769–84.
5. Shchukina O.B. Ivanov S.V., Shotik A.V. Practical recommendations for therapists on the diagnosis and treatment of ulcerative colitis. University Therapeutic Journal. 2021;1:58–70 (In Russ.).
6. Uspenskiy Yu.P., Ivanov S.V., Fominikh Yu.A., Galagudza M.M. Features of inflammatory bowel diseases in St. Petersburg and peculiarities of basic therapy in the regional healthcare system: cross-sectional study results. Experimental and Clinical Gastroenterology. 2021;190(6):29–39 (In Russ.). DOI: 10.31146/1682-8658-ecg-190-6-29-39
7. Belousova E.A., Abdulganiyeva D.I., Alexeyeva O.P., Alekseenko S.A., Baranovskiy A.Yu, Valuyskikh E.Yu., et al. Socialdemographic characteristics, current features and treatment options for inflammatory bowel diseases in Russia. The results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445–63 (In Russ.). DOI: 10.18786/2072-0505-2018-46-5-445-463
8. Khalif L., Shapina M.V., Golovenko A.O., Belousova Y.A., Chashkova Y.Yu., Lakhin A.V., et al. Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study). Rus J Gastroenterol Hepatol Coloproctol. 2018;28(3):54–62 (In Russ.). DOI: 10.22416/1382-4376-2018-28-3-54-62
9. Shapina M.V., Khalif I.L. The use of 5-aminosalicylic acid preparations for the treatment of ulcerative colitis in various dosage regimens. Meditsinskiy sovet = Medical Council. 2017;15:44–50 (In Russ.).
10. Tenjarla S., Abinusawa A. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness. Adv Ther. 2011;28(1):62–72. DOI: 10.1007/s12325-010-0087-5
11. Van de Meeberg M.M., Schultheiss J.P., Oldenburg B., Fidder H.H., Huitema A.D. Does the 5-aminosalicylate concentration correlate with the efficacy of oral 5-aminosalicylate and predict response in patients with inflammatory bowel disease? A Systematic Review. Digestion. 2020;101(3):245–61. DOI: 10.1159/000499331
12. Lachaine J., Yen L., Beauchemin C., Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol. 2013;13:23. DOI: 10.1186/1471-230X-13-23
13. Malayandi R., Kondamudi P.K., Ruby P.K., Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Delivery and Translational Research. 2013;4(2):187–202. DOI: 10.1007/s13346-013-0185-4
14. Cuomo A., Sgambato D., D’Auria M.V., Miranda A., Ferrante E., Romano M. Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis. Dig Dis. 2018;36(2):130–5. DOI: 10.1159/000485614
15. Knyazev O.V., Kagramanova А.V., Lishchinskaya A.A. Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. Meditsinskiy sovet = Medical Council. 2021;(5):113–23 (In Russ.). DOI: 10.21518/2079-701X-2021-5-113-123
16. Yarlas A., Willian M.K., Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res. 2021;30(7):1925–38. DOI: 10.1007/s11136-021-02787-4
Review
For citations:
Uspenskiy Yu.P., Ivanov S.V., Fominykh Yu.A. Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(6):7-15. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-6-7-15
Views:
2189
Email this article 
